Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 15, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

Perimenstrual eletriptan prevents menstrual migraine: an open-label study.

Dawn A Marcus1, Cheryl D Bernstein, Erin A Sullivan

  • 1Department of Anesthesiology & Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

Headache
|March 19, 2010
PubMed
Summary

Perimenstrual eletriptan effectively reduced menstrual migraine (MM) in women. Over half of patients experienced a significant reduction in headache activity, demonstrating the treatment

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Non-Intubated General Anesthesia for Video-Assisted Thoracoscopic Surgery.

Journal of cardiothoracic and vascular anesthesia·2017
Same author

Diagnosis of cardiac tamponade with transesophageal echocardiography following the induction of anesthesia for suspected testicular torsion.

Annals of cardiac anaesthesia·2015
Same author

Case study investigating effect of implementing strategies for reducing patient complaints in an outpatient pain clinic.

Journal of opioid management·2014
Same author

The role of volunteer services at cancer centers.

Current pain and headache reports·2013
Same author

Including a range of outcome targets offers a broader view of fibromyalgia treatment outcome: results from a retrospective review of multidisciplinary treatment.

Musculoskeletal care·2013
Same author

Sumatriptan : treatment across the full spectrum of migraine.

Expert opinion on pharmacotherapy·2013

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Menstrual migraine (MM) significantly impacts women's health.
  • Effective prophylactic treatments for MM are needed.

Purpose of the Study:

  • To evaluate the efficacy of perimenstrual eletriptan for reducing headaches in women with prospectively identified MM.

Main Methods:

  • 126 female migraineurs completed 3 months of headache diaries.
  • Diagnosis of MM was based on International Classification of Headache Disorders (ICHD-II) criteria.
  • Eligible women received perimenstrual eletriptan (20 mg TID) for 6 days per cycle for 3 months.

Main Results:

  • 74% of women were diagnosed with ICHD-II MM; 61 completed treatment.
  • Overall headache activity decreased by 46%.

More Related Videos

A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers
08:33

A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers

Published on: January 5, 2024

Related Experiment Videos

Last Updated: Jun 15, 2026

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache
10:39

3D-Neuronavigation In Vivo Through a Patient's Brain During a Spontaneous Migraine Headache

Published on: June 2, 2014

A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers
08:33

A Randomized, Sham-Controlled Trial of Cranial Electrical Stimulation for Fibromyalgia Pain and Physical Function, Using Brain Imaging Biomarkers

Published on: January 5, 2024

  • 53% of patients achieved 3 migraine-free menstrual periods during treatment.

    • Conclusions:

    • Perimenstrual eletriptan (20 mg TID) is effective in reducing menstrual migraine.
    • A significant reduction in headache activity was observed in over half of the patients treated.